Want to see NVO full AI Analyst Report?

Novo Nordisk (NVO) Stock Forecast & Price Target

14,827 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVO Analyst Ratings

Hold

0 Buy

3 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVO Stock 12 Month Forecast

Average Price Target

$44.67

▲(10.23% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is $44.67 with a high forecast of $47.00 and a low forecast of $42.00. The average price target represents a 10.23% change from the last price of $40.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"$35","68":"$68","43.25":"$43.3","51.5":"$51.5","59.75":"$59.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,43.25,51.5,59.75,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.77,48.63384615384616,48.49769230769231,48.361538461538466,48.22538461538462,48.089230769230774,47.95307692307693,47.816923076923075,47.68076923076923,47.54461538461538,47.40846153846154,47.27230769230769,47.136153846153846,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.77,48.454358974358975,48.138717948717954,47.823076923076925,47.5074358974359,47.191794871794876,46.87615384615385,46.56051282051282,46.24487179487179,45.92923076923077,45.61358974358974,45.297948717948714,44.98230769230769,{"y":44.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.77,48.24923076923077,47.72846153846154,47.20769230769231,46.68692307692308,46.16615384615385,45.645384615384614,45.12461538461539,44.603846153846156,44.08307692307692,43.56230769230769,43.041538461538465,42.52076923076923,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":67.511,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.596,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.025,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.666,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.203,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.199,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.587,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.432,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.88,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.07,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":48.77,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$47.00

Average Price Target$44.67

Lowest Price Target$42.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Nedelcovych

TD Cowen

$42

Hold

3.65%

Upside

Reiterated

06/29/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and Sanofi (NASDAQ: SNY)

Evan Seigerman

BMO Capital

$45

Hold

11.06%

Upside

Reiterated

06/22/26

Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR) and Novo Nordisk (NYSE: NVO)

James Quigley

Goldman Sachs

$41→$47

Hold

15.99%

Upside

Reiterated

06/03/26

Goldman Sachs Sticks to Its Hold Rating for Novo Nordisk (NVO)

Jasper Hellweg

Argus Research

―

Hold

―

Reiterated

03/20/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Addus Homecare (NASDAQ: ADUS) and Novo Nordisk (NYSE: NVO)

Kerry Holford

Berenberg Bank

$57→$47

Buy

15.99%

Upside

Reiterated

03/11/26

Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)

Thibault Boutherin

Morgan Stanley

$42→$40

Hold

-1.28%

Downside

Upgraded

03/03/26

Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley

Martin Brenoe

Nordea Markets

―

Hold

―

Downgraded

02/24/26

Novo Nordisk downgraded to Hold from Buy at NordeaNovo Nordisk downgraded to Hold from Buy at Nordea

Emmanuel Papadakis

Deutsche Bank

―

Hold

―

Downgraded

02/23/26

Novo Nordisk downgraded to Hold from Buy at Deutsche BankNovo Nordisk downgraded to Hold from Buy at Deutsche Bank

Rajesh Kumar

HSBC

$47→$54

Hold

33.27%

Upside

Reiterated

12/10/25

Novo Nordisk price target raised to $54 from $47 at HSBCNovo Nordisk price target raised to $54 from $47 at HSBC

Richard Vosser

J.P. Morgan

―

Buy

―

Reiterated

11/24/25

Novo selloff on Alzheimer's miss overdone, says JPMorganNovo selloff on Alzheimer's miss overdone, says JPMorgan

Sachin Jain

Bank of America Securities

$57.21

Hold

41.19%

Upside

Reiterated

10/09/25

Simon Baker CFA

Rothschild & Co Redburn

―

Buy

―

Upgraded

09/16/25

Novo Nordisk (NVO) was upgraded to a Buy Rating at Redburn Atlantic

Florent Cespedes

Bernstein

―

Buy

―

Upgraded

09/09/25

Novo Nordisk upgraded to Outperform from Market Perform at BernsteinNovo Nordisk upgraded to Outperform from Market Perform at Bernstein

Peter Verdult

Exane BNP Paribas

$54

Hold

33.27%

Upside

Upgraded

08/13/25

Novo Nordisk upgraded to Neutral from Underperform at BNP Paribas ExaneNovo Nordisk upgraded to Neutral from Underperform at BNP Paribas Exane

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Nedelcovych

TD Cowen

$42

Hold

3.65%

Upside

Reiterated

06/29/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and Sanofi (NASDAQ: SNY)

Evan Seigerman

BMO Capital

$45

Hold

11.06%

Upside

Reiterated

06/22/26

Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR) and Novo Nordisk (NYSE: NVO)

James Quigley

Goldman Sachs

$41→$47

Hold

15.99%

Upside

Reiterated

06/03/26

Goldman Sachs Sticks to Its Hold Rating for Novo Nordisk (NVO)

Jasper Hellweg

Argus Research

―

Hold

―

Reiterated

03/20/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Addus Homecare (NASDAQ: ADUS) and Novo Nordisk (NYSE: NVO)

Kerry Holford

Berenberg Bank

$57→$47

Buy

15.99%

Upside

Reiterated

03/11/26

Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)

Thibault Boutherin

Morgan Stanley

$42→$40

Hold

-1.28%

Downside

Upgraded

03/03/26

Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley

Martin Brenoe

Nordea Markets

―

Hold

―

Downgraded

02/24/26

Novo Nordisk downgraded to Hold from Buy at NordeaNovo Nordisk downgraded to Hold from Buy at Nordea

Emmanuel Papadakis

Deutsche Bank

―

Hold

―

Downgraded

02/23/26

Novo Nordisk downgraded to Hold from Buy at Deutsche BankNovo Nordisk downgraded to Hold from Buy at Deutsche Bank

Rajesh Kumar

HSBC

$47→$54

Hold

33.27%

Upside

Reiterated

12/10/25

Novo Nordisk price target raised to $54 from $47 at HSBCNovo Nordisk price target raised to $54 from $47 at HSBC

Richard Vosser

J.P. Morgan

―

Buy

―

Reiterated

11/24/25

Novo selloff on Alzheimer's miss overdone, says JPMorganNovo selloff on Alzheimer's miss overdone, says JPMorgan

Sachin Jain

Bank of America Securities

$57.21

Hold

41.19%

Upside

Reiterated

10/09/25

Simon Baker CFA

Rothschild & Co Redburn

―

Buy

―

Upgraded

09/16/25

Novo Nordisk (NVO) was upgraded to a Buy Rating at Redburn Atlantic

Florent Cespedes

Bernstein

―

Buy

―

Upgraded

09/09/25

Novo Nordisk upgraded to Outperform from Market Perform at BernsteinNovo Nordisk upgraded to Outperform from Market Perform at Bernstein

Peter Verdult

Exane BNP Paribas

$54

Hold

33.27%

Upside

Upgraded

08/13/25

Novo Nordisk upgraded to Neutral from Underperform at BNP Paribas ExaneNovo Nordisk upgraded to Neutral from Underperform at BNP Paribas Exane

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

3 Months

Richard VosserJ.P. Morgan

Success Rate

4/7 ratings generated profit

Average Return

+0.86%

Copying Richard Vosser's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +0.86% per trade.

1 Year

Richard VosserJ.P. Morgan

Success Rate

5/7 ratings generated profit

Average Return

+7.27%

Copying Richard Vosser's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +7.27% per trade.

2 Years

Richard VosserJ.P. Morgan

Success Rate

5/7 ratings generated profit

Average Return

+25.84%

Copying Richard Vosser's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +25.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVO Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVO has received 0 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. NVO average Analyst price target in the past 3 months is 44.67.

Each month's total comprises the sum of three months' worth of ratings.

NVO Financial Forecast

NVO Earnings Forecast

Next quarter’s earnings estimate for NVO is $0.80 with a range of $0.71 to $0.86. The previous quarter’s EPS was $1.04. NVO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NVO has Performed in-line its overall industry.

NVO Sales Forecast

Next quarter’s sales forecast for NVO is $11.00B with a range of $10.70B to $11.66B. The previous quarter’s sales results were $15.16B. NVO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NVO has Performed in-line its overall industry.

NVO Stock Forecast FAQ

What is NVO’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 44.67.

What is NVO’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 10.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NVO a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Hold which is based on 0 buy ratings, 3 hold ratings and 0 sell ratings.

What is Novo Nordisk’s price target?

The average price target for Novo Nordisk is 44.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $47.00 ,the lowest forecast is $42.00. The average price target represents 10.23% Increase from the current price of $40.52.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of NVO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Novo Nordisk (NVO) Stock Forecast & Price Target

NVO Analyst Ratings

NVO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

NVO Analyst Recommendation Trends

NVO Financial Forecast

NVO Earnings Forecast

NVO Sales Forecast

NVO Stock Forecast FAQ

Detailed List of Analyst Forecasts